TP53 and breast cancer: Furthermore, TP53-specific mutation combinations (HRD-high mutations and HRD common mutations) predict the HRD status of patients, which indicates that TP53 pathogenic mutations may serve as potential biomarkers for PARPi in breast cancer patients.